Have You Herd? AABP PodCasts
Have You Herd? AABP PodCasts
Epi. 293 – What do Veterinarian’s Need to Know about Compounding? – Sponsored by Boehringer Ingelheim
Use Left/Right to seek, Home/End to jump to start or end. Hold shift to jump forward or backward.
AABP Executive Director Dr. Fred Gingrich is joined by Dr. Michelle Buckley, Director of Quality Milk Production Services in Warsaw, N.Y. Buckley is also a member of the AABP Committee on Pharmaceutical and Biologic Issues (CPBI) who developed this podcast topic.
This episode is sponsored by Boehringer Ingelheim and the Choose360coverage.com mastitis portfolio. The dairy health portfolio that rises to the challenge is Mastitis 360 by Boehringer Ingelheim. It offers powerful solutions for lactation through dry-off. So, manage udder health with the ultimate tools at your disposal. Because you’re more than a veterinarian. You’re... a hero of the herd. Visit Choose360Coverage.com today.
There are two types of compounding that we discuss. This includes compounding from FDA approved products, such as mixing two anesthetic drugs in the same syringe, or compounding from bulk products, such as having a drug made from the raw active pharmaceutical ingredient or from unapproved FDA drugs. Compounding from bulk products for food animals is prohibited in federal statute found at this link.
FDA further explains their position on compounding from bulk substances for food animals in GFI# 256 that states that FDA generally does not intend to take enforcement action in cases of compounding from bulk substances to produce antidotes for treating toxicoses in food animals or use as sedatives/anesthetics in free-ranging wildlife species.
Buckley also discusses the differences between compounded products and generic animal drugs and the federal regulations on extralabel drug use. It is important for veterinarians to understand the legal allowances for compounding, extralabel drug use. Veterinarians should use the resources provided by the Food Animal Residue Avoidance Databank (FARAD) for assistance with withdrawal intervals when using extralabel drug use or compounded products.
If you are interested in this topic, consider joining the AABP Committee on Pharmaceutical and Biologic Issues. Find AABP committee resources on this page.